Kips Pharma Achieves Cumulative Q3 Revenue of 125 Billion Won... "Sustained Robust Growth"

Kips Biopharma (hereafter Kips Pharma), which has completed its transition to a bio-pharmaceutical company, achieved a cumulative consolidated revenue of 125 billion won in the third quarter of this year. This figure is close to the company’s total revenue for last year and represents a growth of more than 30% compared to the same period last year.

According to the Financial Supervisory Service's electronic disclosure system on November 14, Kips Pharma’s cumulative revenue through the third quarter of this year was 125 billion won, with operating profit reaching 600 million won. Revenue reached an all-time high, increasing by 32% from 94.7 billion won in the same period last year. Operating profit also turned positive, after being slightly in the red through the first half of the year.

On a standalone basis, Kips Pharma’s cumulative revenue for the third quarter was 18.3 billion won, more than quadrupling from 4.4 billion won in the same period last year. It is the first time in three years, since 2022, that Kips Pharma’s standalone revenue has recovered to the triple-digit billion-won level. However, operating profit remained slightly negative, as the company has not yet fully offset the accumulated losses from the OLED division prior to the business unit separation. The company expects that, once fourth-quarter results are reflected, a turnaround will be achieved without difficulty.

The company explained that Kips Pharma’s strong performance is the result of the steady progress made in its pharmaceutical and bio business. Kim Hayong, CEO of Kips Pharma, stated, "A new M&A deal is about to be signed within the year, and we are also planning to introduce new products that will significantly increase our revenue," adding, "We will pursue both external growth and internal stability, and continue to invest in pipeline development without delay."

Meanwhile, Kips Pharma’s subsidiary, Kips Biomed, reportedly held successful meetings with several global big pharma companies and biotech firms at the ‘BIO-Europe 2025’ event earlier this month, entering into follow-up discussions for full-scale partnerships. A Kips Biomed representative said, "Multiple companies showed interest in our 'Oralloyd' technology, and they were particularly impressed by the overwhelming bioavailability data for our oral insulin," adding, "As we have now signed confidentiality disclosure agreements (CDAs) and begun negotiations, we will proceed swiftly with the related procedures to deliver tangible collaborative results."

This content was produced with the assistance of AI translation services.